[go: up one dir, main page]

PE20091949A1 - Formulacion farmaceutica solida con liberacion retardada - Google Patents

Formulacion farmaceutica solida con liberacion retardada

Info

Publication number
PE20091949A1
PE20091949A1 PE2009000568A PE2009000568A PE20091949A1 PE 20091949 A1 PE20091949 A1 PE 20091949A1 PE 2009000568 A PE2009000568 A PE 2009000568A PE 2009000568 A PE2009000568 A PE 2009000568A PE 20091949 A1 PE20091949 A1 PE 20091949A1
Authority
PE
Peru
Prior art keywords
delayed release
pharmaceutical formulation
solid pharmaceutical
polyvinylpyrrolidone
derivative
Prior art date
Application number
PE2009000568A
Other languages
English (en)
Inventor
Venkata-Rangarao Kanikanti
Thomas Bach
Michael Traubel
Gertraut Altreuther
Martina Rehagen
Axel Schmidt
Original Assignee
Bayer Animal Health Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40846135&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20091949(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Animal Health Gmbh filed Critical Bayer Animal Health Gmbh
Publication of PE20091949A1 publication Critical patent/PE20091949A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15—Depsipeptides; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/10—Anthelmintics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Nutrition Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Pain & Pain Management (AREA)
  • Physiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

REFERIDA UN PROCEDIMIENTO PARA PREPARAR UNA FORMULACION FARMACEUTICA SOLIDA CON LIBERACION RETARDADA; QUE COMPRENDE: A) UN INGREDIENTE FARMACEUTICAMENTE ACTIVO SELECCIONADO DE DEPSIPEPTIDO, EMODEPSIDA, PRAZIQUANTEL, METAMIZOL, UN ANALGESICO, LACTONA MACROCICLICA, IVERMECTINA, DERIVADO DE ACIDO FOSFONICO O BUTAFOSFANO; B) POLIVINILPIRROLIDONA O UN DERIVADO DE POLIVIVINILPIRROLIDONA QUE SE ENCUENTRA EN UNA CANTIDAD DE 10-50% p/p; C) UN DISGREGANTE QUE SE ENCUENTRA EN UNA CANTIDAD DE HASTA 5% p/p. DICHA FORMULACION LIBERA EL 80% DEL INGREDIENTE ACTIVO EN UN ENSAYO DE PALETAS, SEGUN FARMACOPEA DE EE.UU, A 37ºC Y 75 REVOLUCIONES POR MINUTO EN CONDICIONES DE IMERSION, EN 1-6 HORAS
PE2009000568A 2008-05-07 2009-04-27 Formulacion farmaceutica solida con liberacion retardada PE20091949A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102008022520A DE102008022520A1 (de) 2008-05-07 2008-05-07 Feste Arzneimittelformulierung mit verzögerter Freisetzung

Publications (1)

Publication Number Publication Date
PE20091949A1 true PE20091949A1 (es) 2009-12-25

Family

ID=40846135

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2009000568A PE20091949A1 (es) 2008-05-07 2009-04-27 Formulacion farmaceutica solida con liberacion retardada

Country Status (29)

Country Link
US (2) US20110046072A1 (es)
EP (1) EP2285359B1 (es)
JP (1) JP5539966B2 (es)
KR (1) KR101663501B1 (es)
CN (1) CN102215824B (es)
AR (1) AR071620A1 (es)
AU (1) AU2009243759B2 (es)
BR (1) BRPI0912428A2 (es)
CA (1) CA2723553C (es)
CL (1) CL2009001016A1 (es)
CO (1) CO6311067A2 (es)
DE (1) DE102008022520A1 (es)
DK (1) DK2285359T3 (es)
DO (1) DOP2010000331A (es)
EC (1) ECSP10010588A (es)
ES (1) ES2393169T3 (es)
IL (1) IL208486A0 (es)
MX (1) MX2010012025A (es)
MY (1) MY159492A (es)
NI (1) NI201000189A (es)
NZ (1) NZ589017A (es)
PE (1) PE20091949A1 (es)
PL (1) PL2285359T3 (es)
PT (1) PT2285359E (es)
RU (1) RU2548733C9 (es)
TW (1) TWI441644B (es)
UA (1) UA103025C2 (es)
UY (1) UY31788A (es)
WO (1) WO2009135593A2 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102258769B1 (ko) * 2011-10-14 2021-06-01 지엘팜텍주식회사 장용소화효소제 및 그 제조방법
UA115232C2 (uk) * 2011-12-21 2017-10-10 Байєр Інтеллектуал Проперті Гмбх Препарат, що містить аморфний емодепсид
KR101400791B1 (ko) * 2012-10-04 2014-05-29 주식회사대성미생물연구소 동물용 복합 기능성 항생제 조성물
MY175703A (en) 2012-12-19 2020-07-06 Bayer Animal Health Gmbh Tablets with improved acceptance and good storage stability
US10682337B2 (en) * 2015-03-03 2020-06-16 Kindred Biosciences, Inc. Compositions and methods for treatment and prevention of pyrexia in horses
AU2016244022A1 (en) 2015-04-02 2017-10-26 Boehringer Ingelheim Animal Health USA Inc. Anthelmintic combinations and methods of use thereof
US10081656B2 (en) 2015-05-20 2018-09-25 Merial, Inc. Anthelmintic depsipeptide compounds
HUE065907T2 (hu) 2015-12-28 2024-06-28 Boehringer Ingelheim Vetmedica Gmbh Anthelmintikus hatású depszipeptid vegyületek
EP3470065A4 (en) * 2016-06-09 2020-03-18 DS Pharma Animal Health Co. Ltd. EXTENDED RELEASE PREPARATION COMPOSITION FOR ANIMALS
EP3541789A1 (en) 2016-11-16 2019-09-25 Boehringer Ingelheim Animal Health USA Inc. Anthelmintic depsipeptide compounds
CN108888598A (zh) * 2018-08-01 2018-11-27 江西成必信生物科技有限公司 口服易吸收的布他磷及其制备方法
JP7268340B2 (ja) * 2018-12-06 2023-05-08 コニカミノルタ株式会社 ３ｄプリンター成形用樹脂組成物及びそれを用いた成形体とその製造方法

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2362539C2 (de) 1973-12-17 1986-05-07 Merck Patent Gmbh, 6100 Darmstadt 2-Acyl-4-oxo-1,2,3,6,7,11b-hexahydro-4H-pyrazino[2,1-a]isochinoline, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
EP0134984B1 (en) 1983-07-16 1988-07-13 Beecham Group Plc Benzazepine and benzoxazepine derivatives
NO176766C (no) * 1989-02-07 1995-05-24 Meiji Seika Kaisha Fremgangsmåte for fremstilling av en forbindelse med anthelmintaktivitet
US5120548A (en) * 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
NL9000238A (nl) * 1990-01-31 1991-08-16 Aesculaap Bv Veterinair fenytoinepreparaat.
DE4139963A1 (de) * 1991-12-04 1993-06-09 Basf Ag, 6700 Ludwigshafen, De Redispergierbares dispersionspulver aus n-vinylpyrrolidon-vinylacetat-copolymerisat, dessen herstellung und verwendung
ES2166359T3 (es) 1992-03-17 2002-04-16 Fujisawa Pharmaceutical Co Derivado de depsipeptido, su produccion y uso.
SE501389C2 (sv) * 1992-04-24 1995-01-30 Leiras Oy Farmaceutiskt preparat och förfarande för dess framställning
DE4317458A1 (de) * 1992-06-11 1993-12-16 Bayer Ag Verwendung von cyclischen Depsipeptiden mit 18 Ringatomen zur Bekämpfung von Endoparasiten, neue cyclische Depsipeptide mit 18 Ringatomen und Verfahren zu ihrer Herstellung
AU666563B2 (en) * 1992-08-07 1996-02-15 Wisconsin Alumni Research Foundation Preparation of 19-nor-vitamin D compounds
AU682827B2 (en) * 1992-09-18 1997-10-23 Astellas Pharma Inc. Sustained-release hydrogel preparation
EP0685469A4 (en) 1993-02-19 1996-04-03 Meiji Seika Kaisha DERIVATIVE OF PF 1022 USED AS A CYCLIC DEPSIPEPTIDE.
DE4317457A1 (de) * 1993-05-26 1994-12-01 Bayer Ag Octacyclodepsipeptide mit endoparasitizider Wirkung
DE4317432A1 (de) * 1993-05-26 1994-12-01 Bayer Ag Octacyclodepsipeptide mit endoparasitizider Wirkung
US5646244A (en) 1993-09-06 1997-07-08 Fujisawa Pharmaceutical Co., Ltd. Cyclodepsipeptide compound
DE4401389A1 (de) * 1994-01-19 1995-07-20 Bayer Ag Verwendung von cyclischen Depsipeptiden mit 12 Ringatomen zur Bekämpfung von Endoparasiten, neue cyclische Depsipeptide mit 12 Ringatomen und Verfahren zu ihrer Herstellung
DE4406025A1 (de) 1994-02-24 1995-08-31 Bayer Ag Milchsäure-haltige cyclische Depsipeptide mit 18 Ringatomen als endoparasitizide Mittel und Verfahren zu ihrer Herstellung
US5747446A (en) * 1994-03-22 1998-05-05 Beth Israel Deaconess Medical Center Modified polypeptides with increased biological activity
EP0758244B2 (en) * 1994-05-06 2008-02-13 Pfizer Inc. Controlled-release dosage forms of azithromycin
DE4437198A1 (de) 1994-10-18 1996-04-25 Bayer Ag Verfahren zur Sulfonylierung, Sulfenylierung und Phosphorylierung von cyclischen Depsipeptiden
JP3985050B2 (ja) 1995-06-30 2007-10-03 アステラス製薬株式会社 デプシペプチド誘導体その製造法およびその新規中間体
DE19531684A1 (de) * 1995-08-29 1997-03-06 Bayer Ag Verfahren zur Herstellung von Arzneimittelzubereitungen mit kontrollierter Freisetzung
CA2232668C (en) 1995-09-22 2011-10-18 Meiji Seika Kaisha, Ltd. Novel derivatives of cyclodepsipeptide pf1022 substance
DE19545639A1 (de) * 1995-12-07 1997-06-12 Bayer Ag Verfahren zur Herstellung von substituierten Arylmilchsäure-haltigen Cyclodepsipeptiden mit 24 Ringatomen
AUPP279698A0 (en) * 1998-04-03 1998-04-30 Sunscape Developments Limited Sustained release formulation
IT1303693B1 (it) * 1998-11-03 2001-02-23 Formenti Farmaceutici Spa Composizioni a rilascio controllato di metamizolo.
DE19920415A1 (de) * 1999-05-04 2000-11-09 Hexal Ag Metamizol enthaltende, kontrolliert freisetzende pharmazeutische Zusammensetzung
US20010053791A1 (en) * 2000-03-16 2001-12-20 Babcock Walter C. Glycogen phosphorylase inhibitor
DE10031044A1 (de) * 2000-06-26 2002-01-03 Bayer Ag Endoparasitizide Mittel zur freiwilligen oralen Aufnahme durch Tiere
EA005537B1 (ru) * 2001-07-10 2005-04-28 Тева Фармасьютикал Индастриес Лтд. Система доставки лекарственного вещества по нулевому порядку, нулевому порядку - двухстадийной, возрастающей или убывающей доставки препарата
US20030190343A1 (en) * 2002-03-05 2003-10-09 Pfizer Inc. Palatable pharmaceutical compositions for companion animals
DE10212864B4 (de) * 2002-03-22 2005-12-22 Beiersdorf Ag Polymermatrizes umfassend ein Mischsystem zur Löslichkeitsvermittlung von pharmazeutischen Wirkstoffen, Verfahren zu deren Herstellung und deren Verwendung
US20040037869A1 (en) * 2002-08-16 2004-02-26 Douglas Cleverly Non-animal product containing veterinary formulations
BRPI0409068A (pt) * 2003-04-02 2006-03-28 Boehringer Ingelheim Int composições farmacêuticas para inibidores de protease viral de hepatite c.
TR200300510A2 (tr) * 2003-04-18 2004-11-22 Sanovel �La� Sanay� Ve T�Caret A.�. Dağılan alendronat mikropartikül formülasyonu
US20050053658A1 (en) * 2003-09-09 2005-03-10 Venkatesh Gopi M. Extended release systems for macrolide antibiotics
US7396819B2 (en) * 2003-08-08 2008-07-08 Virbac Corporation Anthelmintic formulations
DE10351448A1 (de) * 2003-11-04 2005-06-09 Bayer Healthcare Ag Geschmackstoffhaltige Arzneimittelformulierungen mit verbesserten pharmazeutischen Eigenschaften
CA2547657A1 (en) * 2003-12-01 2005-06-16 Lifecycle Pharma A/S Pharmaceutical compositions comprising lercanidipine
DE10358525A1 (de) * 2003-12-13 2005-07-07 Bayer Healthcare Ag Endoparasitizide Mittel zur topischen Applikation
DE102004055316A1 (de) * 2004-11-16 2006-05-18 Bayer Healthcare Ag Verhinderung vertikaler Endoparasiten-Infektionen
US20070275060A1 (en) * 2005-08-05 2007-11-29 Osmotica Costa Rica Sociedad Anonima Extended release solid pharmaceutical composition containing carbidopa and levodopa
US8158152B2 (en) * 2005-11-18 2012-04-17 Scidose Llc Lyophilization process and products obtained thereby
PT2012763E (pt) * 2006-04-28 2011-04-29 Gruenenthal Gmbh Combinação farmacêutica que compreende 3-(3-dimetilamino-1-etil-2-metil-propil)fenol e um aine
WO2008013197A1 (fr) * 2006-07-26 2008-01-31 Asahi Kasei Chemicals Corporation Granulé brut sphérique et son procédé de fabrication
DE102006044694A1 (de) * 2006-09-22 2008-03-27 Krewel Meuselbach Gmbh Perorale feste Schmerzmittelzubereitung
DE102007012644A1 (de) * 2007-03-16 2008-09-18 Bayer Healthcare Ag Stabilisierung von Vitamin B12

Also Published As

Publication number Publication date
TWI441644B (zh) 2014-06-21
EP2285359B1 (de) 2012-09-05
KR20110015592A (ko) 2011-02-16
UY31788A (es) 2009-12-14
JP2011519878A (ja) 2011-07-14
CA2723553C (en) 2016-08-30
BRPI0912428A2 (pt) 2016-02-16
AR071620A1 (es) 2010-06-30
UA103025C2 (ru) 2013-09-10
WO2009135593A2 (de) 2009-11-12
ES2393169T3 (es) 2012-12-19
JP5539966B2 (ja) 2014-07-02
EP2285359A2 (de) 2011-02-23
DOP2010000331A (es) 2010-12-15
RU2548733C2 (ru) 2015-04-20
RU2010149561A (ru) 2012-06-20
KR101663501B1 (ko) 2016-10-07
CO6311067A2 (es) 2011-08-22
NI201000189A (es) 2011-08-10
AU2009243759A1 (en) 2009-11-12
MY159492A (en) 2017-01-13
US20150150985A1 (en) 2015-06-04
MX2010012025A (es) 2010-12-07
DE102008022520A1 (de) 2009-11-12
WO2009135593A3 (de) 2011-01-06
PL2285359T3 (pl) 2013-01-31
RU2548733C9 (ru) 2015-12-20
CL2009001016A1 (es) 2010-08-13
PT2285359E (pt) 2012-11-26
US20110046072A1 (en) 2011-02-24
TW201010714A (en) 2010-03-16
DK2285359T3 (da) 2012-11-26
ECSP10010588A (es) 2010-12-30
AU2009243759B2 (en) 2015-04-16
CN102215824B (zh) 2015-06-03
IL208486A0 (en) 2010-12-30
NZ589017A (en) 2012-11-30
HK1162936A1 (en) 2012-09-07
CN102215824A (zh) 2011-10-12
CA2723553A1 (en) 2009-11-12

Similar Documents

Publication Publication Date Title
PE20091949A1 (es) Formulacion farmaceutica solida con liberacion retardada
ECSP088239A (es) Composición de liberación de fármaco sostenida
WO2010125475A3 (en) Sustained release formulations comprising gnrh analogues
WO2011008298A3 (en) Novel axomadol dosage forms
PE20080765A1 (es) Formas de dosificacion farmaceutica
AR060487A1 (es) Composiciones farmaceuticas de antagonistas del anticuerpo anti- cd40
NI201000193A (es) Formulaciones orales de análogos de citidina y métodos de uso de las mismas.
IN2012DN03130A (es)
DOP2017000294A (es) Unidad de dosificación orodispersable que contiene un componente estetrol
AR059350A1 (es) Formulacion farmaceutica para aerosoles con dos o mas principios activos y al menos una sustancia tensioactiva
GT200600445A (es) Formas de presentación farmaceuticas solidas de administración oral con liberacion rapida del principio activo.
EA201190127A1 (ru) Фармацевтические составы нитазоксанида с контролируемым высвобождением
CL2007003356A1 (es) Compuestos derivados de benzopirazoles; proceso para la preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos y otro agente activo; y su uso para el tratamiento del asma, inflamacion, entre otras enfermedades.
EA201190012A1 (ru) Твердые лекарственные формы бендамустина
CO2017012766A2 (es) Unidad de dosificación orodispersable que contiene un componente estetrol
EA201190161A1 (ru) Способ получения твердых лекарственных форм солифенацина и его фармацевтически приемлемых солей для перорального введения
BR112013004455A2 (pt) composições para fornecimento gástrico de agentes ativos
NZ602441A (en) A fast dissolving pharmaceutical composition
CO6640318A2 (es) Formas de dosificación oral de bendamustina
AR060869A1 (es) Composicion farmaceutica solida de gabapentina
EA201170583A1 (ru) Новая композиция для лечения эссенциальной тромбоцитемии
AR086491A1 (es) Composicion farmaceutica que comprende fexofenadina
EA201390911A1 (ru) Фармацевтическая композиция, содержащая растительное действующее вещество
CL2008000931A1 (es) Particula solidad de vacuna oral entrecruzada que contiene un ingrediente farmaceuticamente activo un bioadhesivo, un oligasacarido, una mezcla mediadiora que comprende un emulsionante y uno o mas monosacaridos y/o disacaridos; metodo para su preparacion; uso de la particula solidad de vacuna oral.
EA201070175A1 (ru) Фармацевтическая композиция контролируемого высвобождения, содержащая толперизона гидрохлорид

Legal Events

Date Code Title Description
FC Refusal